PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 6, 2026Hematology Transfusion and Cell Therapy0 citationsOpen Access

Socio-demographic and therapeutic profile of people living with thalassemia in Brazil between 2012 and 2022: A cross-sectional study

View Full Paper
JGJanaína Rosenburg GioseffiFSFernanda Cristina dos Santos SimãoNMNina Melo

Key Points

  • To outline the sociodemographic and therapeutic profile of individuals with thalassemia in Brazil.
  • Analyzed secondary data from the Ministry of Health on patients with thalassemia.
  • Investigated demographics, geographic location, and clinical outcomes.
  • Utilized outpatient, hospitalization, and mortality information systems.
  • In 2022, 662 patients received outpatient treatment in the Brazilian Unified Health System.
  • 1278 hospitalizations recorded, mainly in children aged 0-9 years.
  • 153 deaths, primarily among individuals aged 50 years or older.

Abstract

OBJECTIVE: To outline the sociodemographic and therapeutic profile of individuals with thalassemia in Brazil between 2012 and 2022, by analyzing data from the Ministry of Health on outpatient care, hospitalization, and mortality records. METHODS: This descriptive, cross-sectional study utilized secondary data from the Outpatient, Hospital, and Mortality Information Systems of the Ministry of Health on patients diagnosed with thalassemia (ICD-10 D56). Analyzed variables included demographics (sex, age, race/ethnicity), geographic location (residence and treatment site), and clinical outcomes (procedures, hospitalizations, and deaths). RESULTS: In 2022, an estimated 662 patients received outpatient treatment in the Brazilian Unified Health System (SUS), with a predominance of young adults, women, and individuals self-identified as White, who were mostly concentrated in the southeastern and southern regions of the country. Red blood cell transfusion was the most frequently performed outpatient procedure during the period. There were 1278 hospitalizations, mainly of children aged 0-9 years. A total of 153 deaths were recorded, primarily among people aged 50 years or older. The findings characterize the patient profile, identify significant travel challenges to receive treatment, and suggest potential underreporting within reference institutions. CONCLUSION: It is essential to improve data recording in public databases to support specific health policies and ensure comprehensive, equitable, and continuous treatment for people living with thalassemia in Brazil.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Gioseffi et al. (2026) studied this question.

synapsesocial.com/papers/69fa8ef304f884e66b5314c9https://doi.org/10.1016/j.htct.2026.106461
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Long-term efficacy and safety of luspatercept for the treatment of anaemia in patients with transfusion-dependent β-thalassaemia (BELIEVE): final results from a phase 3 randomised trial2025 · 20 citations
  2. 2Distribuição das mutações da β-talassemia em Fortaleza, Ceará2010 · 5 citations
  3. 3β-Thalassemia: all about that base, no cutting2023 · 2 citations
  4. 4Global, regional, and national burden of thalassemia, 1990–2021: a systematic analysis for the global burden of disease study 20212024 · 302 citations
  5. 5Desigualdades de gênero e raciais no acesso e uso dos serviços de atenção primária à saúde no Brasil2021 · 182 citations